Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2

Files

Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.pdf (665.94 KB)

Date

2011

Authors

Erdag, B.
Koray Balcioglu, B.
Ozdemir Bahadir, A.
Serhatli, M.
Kacar O.
Bahar, A.
Seker, U.O.S.
Akgun, E.
Ozkan, A.
Kilic, T.

Editor(s)

Advisor

Supervisor

Co-Advisor

Co-Supervisor

Instructor

BUIR Usage Stats
4
views
44
downloads

Citation Stats

Attention Stats

  • Share

Series

Abstract

Human vascular endothelial growth factor (VEGF) and its receptor (VEGFR-2/kinase domain receptor [KDR]) play a crucial role in angiogenesis, which makes the VEGFR-2 signaling pathway a major target for therapeutic applications. In this study, a single-chain antibody phage display library was constructed from spleen cells of mice immunized with recombinant human soluble extracellular VEGFR-2/KDR consisting of all seven extracellular domains (sKDR D1-7) to obtain antibodies that block VEGF binding to VEGFR-2. Two specific single-chain antibodies (KDR1.3 and KDR2.6) that recognized human VEGFR-2 were selected; diversity analysis of the clones was performed by BstNI fingerprinting and nucleotide sequencing. The single-chain variable fragments (scFvs) were expressed in soluble form and specificity of interactions between affinity purified scFvs and VEGFR-2 was confirmed by ELISA. Binding of the recombinant antibodies for VEGFR-2 receptors was investigated by surface plasmon resonance spectroscopy. In vitro cell culture assays showed that KDR1.3 and KDR2.6 scFvs significantly suppressed the mitogenic response of human umbilical vein endothelial cells to recombinant human VEGF 165 in a dose-dependent manner, and reduced VEGF-dependent cell proliferation by 60% and 40%, respectively. In vivo analysis of these recombinant antibodies in a rat cornea angiogenesis model revealed that both antibodies suppressed the development of new corneal vessels (p < 0.05). Overall, in vitro and in vivo results disclose strong interactions of KDR1.3 and KDR2.6 scFvs with VEGFR-2. These findings indicate that KDR1.3 and KDR2.6 scFvs are promising antiangiogenic therapeutic agents. © 2011 International Union of Biochemistry and Molecular Biology, Inc.

Source Title

Biotechnology and Applied Biochemistry

Publisher

Course

Other identifiers

Book Title

Keywords

antiangiogenic, corneal angiogenesis assay, HUVEC, phage display, single-chain variable fragment (scFv), vascular endothelial growth factor receptor-2 (VEGFR-2), Angiogenesis, Antiangiogenic, HUVEC, phage display, Single chain variable fragments, Vascular endothelial growth factor, Animal cell culture, Assays, Cell proliferation, Endothelial cells, Peptides, Plants (botany), Surface plasmon resonance, Antibodies, vasculotropin antibody, vasculotropin receptor 2, angiogenesis, animal cell, animal experiment, article, binding affinity, biopanning, cell proliferation, controlled study, cornea, DNA fingerprinting, DNA sequence, enzyme linked immunosorbent assay, human, human cell, human tissue, in vitro study, in vivo study, male, mouse, nonhuman, phage display, protein binding, protein domain, rat, spleen cell, surface plasmon resonance, Amino Acid Sequence, Angiogenesis Inhibitors, Animals, Base Sequence, Cell Proliferation, Cornea, Dose-Response Relationship, Immunologic, Enzyme-Linked Immunosorbent Assay, Human Umbilical Vein Endothelial Cells, Humans, Male, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Peptide Library, Rats, Recombinant Proteins, Single-Chain Antibodies, Spleen, Surface Plasmon Resonance, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2

Degree Discipline

Degree Level

Degree Name

Citation

Permalink

http://hdl.handle.net/11693/21723

Published Version (Please cite this version)

http://dx.doi.org/10.1002/bab.61

Collections

Scholarly Publications - UNAM
Scholarly Publications - NANOTAM

Language

English

Type

Article